Lọc theo danh mục
  • Năm xuất bản
    Xem thêm
  • Lĩnh vực
liên kết website
Lượt truy cập
 Lượt truy cập :  29,935,992
  • Công bố khoa học và công nghệ Việt Nam

76.29.40

Y học lâm sàng

Nguyễn Mai Hồng, Tran Viet Hung(1)

Nghiên cứu hiệu quả và tính an toàn của Infliximab (Remicade) sau 14 tuần điều trị bệnh viêm cột sống dính khớp

Evaluation of effect and safety of infuximab (remicade) for 14 - week treatment of ankylosing spondylitis

Y học Việt Nam

2014

2

112-117

1859-1868

Objectives: To evaluate the effect and safety of Infliximab (Remicade) for 14 - week treatment of Ankylosing Spondylitis (AS). Subjects and Methods: This prospective, descriptive, cross sectional study was carried out on 60 in patients diagnosed with AS according to ACR - 1984 criteria at Bach mai Hospital and E Hospital. The patients were divided into two groups, Including group 1: 30 consecutive patients treated with Sufasalazine and Non - steroidal anti inflammatory drugs (NSAIDs), and group 2: 30 others treated with Infliximab and NSAIDs during 14 weeks. Results. After 14 - week duration of study, group 2 had significant improvement in noctunal back pain, BASDAI, BASA, spinal mobility, reduction of dose of NSAIDs used concomitantly, CRP level and erythrocyte sedimentation rate. Infliximab treatment were generally well tolerated, there were no dlscontlmuations for safety reasons. Conclusion. Inflixlmab is effective and safe for treatment of Vietnamese patient with Ankylosing Spondylitis.

TTKHCNQG, CVv 46